Merck's Vaccine Highly Effective in Cervical Cancer Prevention

DECEMBER 01, 2005
Susan Farley

A phase 3 study showed that Gardasil, an investigational vaccine from Merck, prevented 100% of high-grade cervical precancers and noninvasive cervical cancers associated with human papillomavirus (HPV) types 16 and 18. This worldwide, prospective, randomized, double-blind, placebo-controlled study, known as FUTURE II, included more than 12,000 women, with 6082 receiving Gardasil and 6075 receiving a placebo. The study evaluated the incidence of HPV 16/18-related cervical precancers and noninvasive cancers and the cervical lesions related to these cancers, which are precursors to invasive squamous cell cervical cancer. In the group receiving a regimen of Gardasil, no cases of highgrade precancer and noninvasive cancer associated with HPV 16/18 were present, compared with 21 cases in the placebo group. Merck expects to submit a Biologics License Application to the FDA by the end of this year.

Ms. Farley is a freelance medical writer based in Wakefield, RI.




SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.